-
Cancer Drug Response Beyond Viability
2026-10-07
Hannah Schwartz’s 2022 dissertation distinguishes relative viability from fractional viability, showing why a single endpoint can obscure the balance between proliferative arrest and cell death. Its central contribution is an interpretive framework for separating growth inhibition from killing, while recognizing that both processes may occur with different magnitudes and timing.
-
KR-12 in Mouse Models of Colitis
2026-10-07
The reference study evaluated the LL-37 fragment KR-12 across four chemically induced mouse models of colitis and found reduced inflammatory injury, myeloperoxidase activity in one model, and selected bacterial measures. Its main contribution is a preclinical rationale for studying KR-12 as a dual anti-inflammatory and antibacterial candidate, while the results remain limited to animal models and do not establish efficacy or safety in human inflammatory bowel disease.
-
Caffeic Acid Phenethyl Ester: A Pathway Probe
2026-10-06
Caffeic Acid Phenethyl Ester (CAPE) is best interpreted as a mechanistic NF-κB pathway probe rather than a stand-alone disease model. This article places CAPE alongside recent Fyn–STAT3–NF-κB zebrafish evidence, clarifying what the compound can test, what it cannot establish, and where oncology findings remain context-dependent.
-
(Z)-4-Hydroxytamoxifen: Evidence Overview
2026-10-06
This overview examines (Z)-4-Hydroxytamoxifen as a selective estrogen receptor research tool, separating supplier-reported pharmacology from independently supported conclusions. It discusses estrogen receptor signaling, conceptual applications in endocrine oncology, evidence comparison, and the limits of extrapolating preclinical or unrelated disease-model findings to human breast cancer.
-
Rotigotine Hydrochloride: Evidence and Research Context
2026-10-05
Rotigotine hydrochloride is a dopamine D2/D3 receptor agonist used in Parkinson’s disease research and related dopaminergic signaling studies. A rat model study found route-dependent effects on bladder contraction intervals and voiding pressure, but the findings do not establish clinical efficacy or D2/D3-selective action.
-
4-Methoxychalcone-1 and Retinal Angiogenesis
2026-10-04
Explore how 4-Methoxychalcone-1 should be positioned in research on hypoxia, vascular stability, and retinal angiogenesis. This evidence-focused analysis separates product identity from scutellarin findings and explains what the VEGF/Ang/Tie2 study does—and does not—establish.
-
Rotigotine Hydrochloride and Bladder-Brain Biology
2026-10-03
Rotigotine hydrochloride is more than a dopamine D2/D3 receptor agonist for motor research. This article examines its route-dependent effects on lower urinary tract function, the translational meaning of the evidence, and how bladder outcomes can refine Parkinson’s disease research.
-
WNT5a/GSK3/β-Catenin Controls FAP Adipogenesis
2026-10-02
The reference study identifies the WNT5a/GSK3/β-catenin axis as a central regulator of adipogenic drift in skeletal muscle fibro/adipogenic progenitors. By integrating pharmacological perturbation, mass cytometry, animal models, and transcriptomic network analysis, it links restoration of β-catenin activity with reduced fatty degeneration and improved muscle-supportive FAP function.
-
Radioiodinated Balsalazide for Ulcerative Colitis Imaging
2026-10-01
Sanad and colleagues developed and evaluated radioiodinated balsalazide as a colon-targeted tracer for murine ulcerative colitis. The optimized labeling workflow produced a stable radiotracer and showed markedly increased uptake in ulcerated colon, supporting its use as a preclinical imaging tool while leaving human translation and receptor-specific mechanisms unresolved.
-
D-Luciferin for Mechanistic Tumor Immunotherapy BLI
2026-10-01
D-Luciferin enables firefly luciferase substrate readouts that connect tumor-targeted immunotherapy design with longitudinal bioluminescence imaging. This article explains how to interpret reporter signals without confusing tumor burden, promoter activity, and intracellular ATP.
-
7-dehydro Cholesterol: From Sterol Flux to Immunity
2026-09-30
Explore how 7-dehydro Cholesterol connects DHCR7-dependent sterol flux with vitamin D3 formation, oxidative lipid biology, and antiviral phenotypes. This article translates recent grass carp gene-editing evidence into practical assay and interpretation strategies.
-
SuperSignal ECL Chemiluminescent Substrate Detection Kit
2026-09-30
Translate multi-omics candidates such as ALOX5 into sensitive, quantifiable Western blot evidence with a workflow designed for low-abundance proteins. The SuperSignal ECL Kit Ultrasensitive combines extended signal persistence with film- or imager-compatible detection for tissue and primary-cell studies.
-
Forsythoside E in Cell Assay Workflows
2026-09-29
Learn how Forsythoside E (SKU N2883) can help researchers separate metabolic assay effects from true cytotoxicity in RAW264.7 macrophage experiments. This scenario-based guide covers dose selection, serum compatibility, interpretation, handling, and vendor-quality checks for immunometabolic and sepsis-induced liver injury research.
-
Intestinal Stretch, Weight Loss, and Glucose Control
2026-09-29
The reference study identifies intestinal mechanical stretch as an acute regulator of feeding and oral glucose tolerance that operates independently of classical GLP-1 signaling. Using dietary and surgical weight-loss models, it shows that obesity weakens this gut–brain response, whereas weight loss restores intestinal stretch-induced satiety and nucleus of the solitary tract activation.
-
Cepharanthine for Endometriosis Research
2026-09-28
Cepharanthine offers a practical way to test growth suppression, DNA damage, and apoptosis across endometrial cell models, patient-derived organoids, and lesion models. This workflow emphasizes matched vehicle controls and mechanism-linked readouts so promising preclinical signals are easier to interpret—not mistaken for clinical efficacy.